Description
Human Serum is a highly sensitive material and is subject to strict safety EU regulations. The donor material is taken from healthy human volunteers by certified donation institutions in Europe. The collection of blood follows the EU standards (Directive 2002/98/EC - quality and safety standards for the collection, testing, processing, storage and distribution of human blood and blood components).
According to the EU standards, the donors were tested for the following infection parameters: HBsAg, HBV DNA, anti-HCV, HCV RNA, anti-HIV, HIV RNA and Lues serology. It is possible to exclude the window period in case of NAT and antibodies/antigen tests (e.g. HBsAg and HBV NAT) with the current state of the art testing according to EU guidelines.
From the collection of the plasma up to the packaging of the final product, each individual production step is controlled and well documented. Therefore, we provide our customers with characterized sera of consistently high quality and an absolute maximum level of safety and transparency.
Pooled human plasma units are converted into serum by defibrinating the plasma, filtered and bottled. The final serum product undergoes extensive quality control testing before it is released for distribution.
However, human serum products should always be considered as potentially infectious and handled accordingly. Heat Inactivated or Gamma Irradiated serum is available on request.
Composition
Human serum is produced from human plasma by addition of calcium chloride. This results in clotting of the plasma. After the coagulation process the cellular and solid constituents of the serum are removed by centrifugation, the human serum is washed and concentrated by ultra-filtration and finally filtered through a combination of depth- and membrane- filters. Serum is component of the blood, therefore it contains a complex composition of serum proteins, growth factors, hormones, lipids, amino acids, sugar, etc. Thereby serum is a broadly suitable cell culture media supplement.
Applications
- Alternative to fetal bovine serum (FBS).
- Cell culture media supplement.
- Suitable for a wide variety of cells, particularly for human cells.
- Regenerative medicine research.
- Tissue engineering research.
- Human MSCs proliferated considerably more rapidly in the presence of Human Serum than with FBS.
- Blocking agent for immunohistochemical (IHC) staining procedures.
- Leukocyte antigen (HLA) typing.
Human serum may be more suitable for the cultivation of human cells than FBS since serum and the cultured cells belong to the same species. Thus the physiological and natural conditions in vitro are reproduced most similar to those in vivo. Human serum is particularly suitable for cell culture of human cells, tissue engineering of human tissue, sensitive cell lines, and immune cells.
Advantages
- Low lot-to-lot variation.
- Reproducible growth properties.
- Low endotoxin level.
- Continuous quality control.
- Heat Inactivated or Gamma Irradiated available by request.
Specifications
| Species of Origin: | Human |
|---|---|
| Pooled/Single-Donor: | Pooled |
| Donor Blood Type: | Unspecified |
| Donor Sex: | Unspecified |
| Endotoxin Content: | Endotoxin content unspecified |
| Filter Pore Size: | 0.2 µm |
| Liquid / Powder: | Liquid |
| Product Category: | Human Serum |
| Product Type: | Human Serum |
| Size: | 100 ml or 500 ml bottles |
| Sterile: | Yes |
| Storage Temperature: | -20°C |
| Manufacturer: | PAN-Biotech GmbH |
| Country of Origin: | EU Origin |
Application Note
Human serum is usually used in a concentration between 5% and 15%. Cells cultured with FBS should be adapted step by step to the new serum. Initially, the cells should be cultivated for 4-6 days with a 10% serum mixture, consisting of 4% FBS and 6% human serum. Afterwards the final conversion to human serum can take place.
Usage
This product is intended for Laboratory Research Use Only. Not for use in diagnostic or therapeutic procedures. This product may not be used as a pharmaceutical or veterinary drug, agricultural product, or food additive.
Resources
Product References
- Abdurrahman, Goran et al. “The extracellular serine protease from Staphylococcus epidermidis elicits a type 2-biased immune response in atopic dermatitis patients.” Frontiers in immunology vol. 15 1352704. 4 Jun. 2024, doi:10.3389/fimmu.2024.1352704
- Nordengrün, Maria et al. “Allergic Reactions to Serine Protease-Like Proteins of Staphylococcus aureus.” Frontiers in immunology vol. 12 651060. 23 Mar. 2021, doi:10.3389/fimmu.2021.651060
Related Products
Ilex Life Sciences LLC is an authorized distributor of PAN-Biotech GmbH.